UAB’s Director Of Infectious Diseases Warns Caution Around COVID-19 Vaccines In Trial
Dr. Jeanne Marrazzo speaks during a press conference September 3, 2020.
The director of infectious diseases at the University of Alabama at Birmingham says right now she would not take one of the COVID-19 vaccines currently in phase three clinical trials across the country.
During a press conference Thursday, Dr. Jeanne Marrazzo addressed the Centers for Disease Control’s announcement that a vaccine could be ready by the end of October. She said the vaccines have been fast-tracked and not much is known about their long term effects or success rates.
“Yes, I know there’s urgency, but we should not sacrifice our convenience for the rush to get a product that we just don’t know is really truly safe,” Marrazzo said. “We deserve the best. We deserve better. I mean people have been through hell with this thing.”
Efficacy trials, or better known as phase three trials, help determine if a vaccine works. In the case of COVID-19, for a phase three trial to be successful it must show that the vaccine reduces the number of actual infections in people and that participants are able to make antibodies against the virus over time.
But now, Marrazzo said, those efficacy standards may change with the release of data from a vaccine trial in the United Kingdom earlier this week.
“My big concern about this timeline that’s now out there is that not only do we not have the kind of evidence for efficacy, yet. Yet. I’m saying yet because maybe they know something I don’t know. That’s always possible,” Marrazzo said. “But do we really have confidence that we can go out there and vaccinate everybody safely without knowing the longer-term benefits or side effects of this vaccine?”
Marrazzo said she is also concerned that there is not enough information yet about long-lasting immunity to COVID-19, especially given recent reports of people being reinfected with the virus. She noted that the vaccines are based on a totally new technology.
“We have never had a messenger RNA vaccine in a human population before these trials,” Marrazzo said. “We think it’s safe, but we don’t know.”
She added that vaccines can have serious side effects. Marrazzo said phase three trials typically follow participants for at least a year, if not longer, to track possible side effects. If a vaccine is released in late October, it would have only been studied in humans for eight months – at most.
“We need iron-clad proof and assurance to the extent that anybody can get it in any vaccine study or any medical study that whatever product we make widely available to our citizens is as safe and effective as humanly possible,” Marrazzo said. “We are not there, right now. There’s no way I have seen, myself, and I know that most experts have seen enough data to feel like not only today there’s something to roll out but in seven short weeks … that there would be something to roll out.”
Marrazzo said ultimately the decision to get the vaccine is a risk-benefit analysis, but she will not get one unless it is backed by the Advisory Committee on Immunization Practices. Meanwhile, Marrazzo said she plans on volunteering for a vaccine clinical trial.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Mourners grieve 10-year-old slain in Bondi mass shooting as Australia’s leader pledges new hate laws
Hundreds of mourners bearing bright bouquets and clutching each other in grief gathered at a funeral in Sydney on Thursday for a 10-year-old girl who was gunned down in an antisemitic massacre during a Hanukkah celebration at Bondi Beach.
US announces massive package of arms sales to Taiwan valued at more than $10 billion
The Trump administration has announced a massive package of arms sales to Taiwan valued at more than $10 billion that includes medium-range missiles, howitzers and drones, a move that is sure to infuriate China.
Pulitzer Prize-winning correspondent Peter Arnett has died
Peter Arnett, the Pulitzer Prize-winning reporter who spent decades dodging bullets and bombs to bring the world eyewitness accounts of war from Vietnam to Iraq, has died. He was 91.
FBI Deputy Director Dan Bongino says he will step down in January
Bongino's tenure was at times tumultuous, including a clash with Justice Department leadership over the Epstein files. But it also involved the arrest of a suspect in the Jan. 6 pipe bomber case.
Federal court says troops can stay in D.C., and hints at prolonged deployment
A federal appeals court in Washington, D.C. has ruled that National Guard troops can remain in the city for now. That decision comes after a different federal appeals court ruled that troops must leave Los Angeles earlier this week.
Jack Smith defends his prosecutions of Trump in closed-door session in Congress
The former Justice Department special counsel told the House Judiciary Committee that his team developed "proof beyond a reasonable doubt" that Trump took part in a criminal scheme to overturn the 2020 election.
